Moreover, recent studies elegantly demonstrated that high TGFβ signaling in metastatic tumor margins contributes to reduced immune surveillance and poor therapy response in metastatic colorectal (53) and urothelial (54) cancers. This evidence concerns the gene TGFB1 and cancer.